Global generic pharmaceuticals company Alvogen, with its U.S. base in the Pine Brook section of Montville Township, announced today it has acquired U.S. commercialization rights for a controlled-release pain killer from Florham Park-based Shionogi Inc.
According to the announcement, the nonsteroidal anti-inflammatory Naprelan is manufactured in controlled-release tablets at dosages of 375 mg, 500 mg and 750 mg. The product will be marketed by Almatica Pharma Inc., a subsidiary of Alvogen. In a separate transaction, Alvogen also acquired all rights and interest in the new drug application to the U.S. Food and Drug Administration for Naprelan from Pa.-based Stat-Trade Inc.
Financial terms of the transaction were not disclosed, but Naprelan had annual U.S. sales of $58 million in 2012, the company said in a statement.
The company announced Darren Alkins as its new president in October.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy